8.1K(top 4%)
articles
304.7K(top 3%)
citations
2,792(top 3%)
★★ articles
147(top 2%)
★★★ articles
2.8(top 16%)
Avg IF
217(top 2%)
H-Index
353(top 2%)
G-Index
1,277
journals

Most Cited Articles of Hôpital Saint-Louis in 2020

TitleJournalYearCitations
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19Science2020994
Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert CommitteeJournal of Clinical Immunology2020497
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemiaLeukemia2020356
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studyLancet Oncology, The2020281
Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical ClassificationJournal of Clinical Immunology2020267
Acute kidney injury in critically ill patients with COVID-19Intensive Care Medicine2020226
Luspatercept in Patients with Lower-Risk Myelodysplastic SyndromesNew England Journal of Medicine2020160
Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19Blood2020147
Symptoms of burnout in intensive care unit specialists facing the COVID-19 outbreakAnnals of Intensive Care2020122
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow TransplantationLancet Haematology,the2020116
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension studyLancet Haematology,the2020107
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDSBlood202072
Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)Journal of Clinical Oncology202069
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphomaBlood Advances202058
British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritisRheumatology202057
The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guidelineIntensive Care Medicine202055
Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohortClinical Microbiology and Infection202055
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trialLeukemia202054
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 studyLancet Haematology,the202052
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE studyLeukemia and Lymphoma202050
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failureAmerican Journal of Hematology202045
Synergistic effects of PRIMA-1 (APR-246) and 5-azacitidine in -mutated myelodysplastic syndromes and acute myeloid leukemiaHaematologica202045
High total metabolic tumor volume at baseline predicts survival independent of response to therapyBlood202041
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international expertsLancet Haematology,the202041
Increased mortality in patients with severe SARS-CoV-2 infection admitted within seven days of disease onsetIntensive Care Medicine202040